Ask AI
ProCE Banner Activity

evERA: Clinical and Biomarker Subgroup Analysis of Giredestrant + Everolimus in ER+/HER2− ABC Previously Treated with a CDK4/6 Inhibitor

Conference Coverage
Slideset

In the subgroup analysis from the phase III evERA trial, the combination of giredestrant plus everolimus compared with SoC ET shows clinically meaningful and statistically significant improvement in investigator-assessed PFS regardless of ESR1 mutation and PIK3CA/AKT1/PTEN alteration status and prior CDK4/6 inhibitor duration and choice.

Released: December 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer